Boston Trust Walden Corp Purchases New Position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Boston Trust Walden Corp bought a new stake in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 178,012 shares of the specialty pharmaceutical company's stock, valued at approximately $22,100,000. Boston Trust Walden Corp owned 0.29% of Jazz Pharmaceuticals at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the stock. Friedenthal Financial purchased a new stake in Jazz Pharmaceuticals during the 1st quarter valued at about $858,000. Johnson Investment Counsel Inc. boosted its holdings in Jazz Pharmaceuticals by 5.1% during the 1st quarter. Johnson Investment Counsel Inc. now owns 20,790 shares of the specialty pharmaceutical company's stock valued at $2,581,000 after acquiring an additional 1,000 shares during the period. State of Alaska Department of Revenue boosted its holdings in Jazz Pharmaceuticals by 0.6% during the 1st quarter. State of Alaska Department of Revenue now owns 33,083 shares of the specialty pharmaceutical company's stock valued at $4,106,000 after acquiring an additional 190 shares during the period. Cardinal Capital Management boosted its holdings in Jazz Pharmaceuticals by 0.9% during the 1st quarter. Cardinal Capital Management now owns 13,254 shares of the specialty pharmaceutical company's stock valued at $1,645,000 after acquiring an additional 114 shares during the period. Finally, Janney Montgomery Scott LLC purchased a new stake in Jazz Pharmaceuticals during the 1st quarter valued at about $1,888,000. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,000 shares of the business's stock in a transaction that occurred on Thursday, May 1st. The stock was sold at an average price of $116.35, for a total transaction of $116,350.00. Following the sale, the chief executive officer now directly owns 439,307 shares of the company's stock, valued at $51,113,369.45. The trade was a 0.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Seamus Mulligan bought 100,000 shares of the company's stock in a transaction on Friday, May 9th. The shares were acquired at an average price of $98.26 per share, with a total value of $9,826,000.00. Following the transaction, the director now directly owns 100,000 shares of the company's stock, valued at approximately $9,826,000. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have sold 3,000 shares of company stock worth $355,925 over the last ninety days. Corporate insiders own 4.30% of the company's stock.

Analysts Set New Price Targets

A number of research firms have commented on JAZZ. Cantor Fitzgerald lowered Jazz Pharmaceuticals from an "overweight" rating to a "neutral" rating and upped their price target for the company from $140.00 to $150.00 in a research report on Wednesday, February 26th. UBS Group raised Jazz Pharmaceuticals from a "neutral" rating to a "buy" rating and upped their price target for the company from $145.00 to $179.00 in a research report on Friday, March 7th. Piper Sandler reaffirmed an "overweight" rating and set a $147.00 price target (down previously from $176.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, May 7th. Robert W. Baird lowered their price target on Jazz Pharmaceuticals from $167.00 to $155.00 and set an "outperform" rating for the company in a research report on Wednesday, May 7th. Finally, Morgan Stanley lowered their price target on Jazz Pharmaceuticals from $183.00 to $166.00 and set an "overweight" rating for the company in a research report on Wednesday, May 7th. Two investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. According to MarketBeat.com, Jazz Pharmaceuticals has an average rating of "Moderate Buy" and an average target price of $184.00.

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ stock traded down $0.75 on Monday, reaching $106.76. The stock had a trading volume of 509,761 shares, compared to its average volume of 826,185. The stock has a market cap of $6.46 billion, a P/E ratio of 14.23, a price-to-earnings-growth ratio of 4.64 and a beta of 0.33. Jazz Pharmaceuticals PLC has a 1 year low of $95.49 and a 1 year high of $148.06. The company has a debt-to-equity ratio of 1.28, a quick ratio of 2.97 and a current ratio of 3.38. The company has a 50 day simple moving average of $108.24 and a 200 day simple moving average of $119.92.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last released its earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share for the quarter, missing the consensus estimate of $4.65 by ($2.97). The company had revenue of $897.84 million for the quarter, compared to analysts' expectations of $984.16 million. Jazz Pharmaceuticals had a net margin of 11.86% and a return on equity of 26.62%. Jazz Pharmaceuticals's revenue for the quarter was down .5% on a year-over-year basis. During the same quarter last year, the firm posted $2.68 earnings per share. Equities research analysts expect that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current year.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.